Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (ARTESIA)

Authors, Journal, Affiliations, Type, DOI

• Healey JS, Lopes RD, Granger CB, Alings M, Rivard L, McIntyre WF, et al. (ARTESIA Investigators)
• Population Health Research Institute, McMaster University, Hamilton, ON (lead); 247 sites across 16 countries
• New England Journal of Medicine, 2024;390(2):107-117
• Phase 3 double-blind, double-dummy randomized controlled trial
• DOI: 10.1056/NEJMoa2310234
• Funding: Canadian Institutes of Health Research (primary, peer-reviewed); Bristol-Myers Squibb–Pfizer Alliance (drug supply + funding; no role in analysis)

Overview

The ARTESIA trial enrolled 4,012 patients with CIED-detected subclinical AF lasting 6 minutes to 24 hours and CHA₂DS₂-VASc ≥3, randomizing them to apixaban 5 mg BID vs aspirin 81 mg daily in a double-blind design. After a mean 3.5-year follow-up, apixaban reduced stroke or systemic embolism by 37% (HR 0.63; P=0.007) and disabling/fatal stroke by 49% (HR 0.51), while increasing major bleeding 1.8× (HR 1.80; P=0.001). Crucially, 90% of major bleeds were managed without invasive procedures, and fatal bleeding and intracranial haemorrhage rates did not differ significantly between groups, whereas 45% of strokes in the aspirin arm caused permanent disability or death — supporting a net clinical benefit favouring anticoagulation at this CHA₂DS₂-VASc threshold. This trial contradicts the neutral NOAH-AFNET 6 result (edoxaban vs placebo), with the discordance explained by NOAH's underpowering, diluted composite primary outcome, and placebo comparator.

Keywords

Subclinical atrial fibrillation, SCAF, atrial high-rate episodes, AHRE, apixaban, anticoagulation, stroke prevention, pacemaker, ICD, implantable cardiac monitor, ARTESIA

Key Takeaways

Study Design

• Double-blind, double-dummy RCT; 4,012 patients; 247 sites; 16 countries (European and North American)
• Enrollment: May 2015 – July 2021
• Eligible: CIED-detected SCAF ≥6 minutes but no episode >24 hours; CHA₂DS₂-VASc ≥3; age ≥55 years (protocol amendment)
• Exclusions: prior clinical AF, ongoing OAC indication, uncorrected major bleeding in prior 6 months, CrCl <25 mL/min
• Randomization: apixaban 5 mg BID (2.5 mg BID if meeting dose-reduction criteria) vs aspirin 81 mg daily
• If SCAF >24 h or clinical AF developed → trial drug stopped, open-label OAC initiated; patient continued in follow-up
• Mean age: 76.8±7.6 years; 36.1% women; mean CHA₂DS₂-VASc 3.9±1.1
• Median longest SCAF episode in prior 6 months: 1.47 hours (IQR 0.20–4.95)
• Open-label aspirin pre-randomization: 57.4% of patients
• Mean follow-up: 3.5±1.8 years (ITT); 2.5±1.8 years (on-treatment)
• Trial discontinued: ~24% per arm progressed to SCAF >24h or clinical AF (median time 18.3 months); ~35% per arm discontinued for other reasons

Primary Efficacy Results

• Stroke or systemic embolism (ITT): Apixaban 0.78%/yr vs aspirin 1.24%/yr — HR 0.63 (95% CI 0.45–0.88; P=0.007)
• 37% relative risk reduction in primary endpoint
• Ischemic stroke (including unknown cause): HR 0.62 (95% CI 0.43–0.91)
• Stroke from any cause: HR 0.64 (95% CI 0.46–0.90)
• Disabling or fatal stroke (mRS 3–6): 18/55 (33%) with apixaban vs 36/84 (43%) with aspirin — HR 0.51 (95% CI 0.29–0.88); 49% lower risk
• On-treatment analysis: stroke/SE HR 0.55 (95% CI 0.37–0.83; P=0.004)
• No significant subgroup interactions for any prespecified subgroup

Primary Safety Results

• Major bleeding (on-treatment): Apixaban 1.71%/yr vs aspirin 0.94%/yr — HR 1.80 (95% CI 1.26–2.57; P=0.001)
• Fatal bleeding: 5 apixaban vs 8 aspirin (not significantly different)
• Symptomatic intracranial haemorrhage: 12 apixaban vs 15 aspirin (not significantly different)
• Most major bleeding was mild in severity: 90% managed with non-procedural measures (including transfusion)
• Haemodynamic instability or neurological symptoms at bleeding presentation: 17/93 (18%) apixaban vs 13 aspirin
• Immediate life-saving measures or death from bleeding: 9/93 (10%) apixaban vs 4 aspirin

Net Benefit Framing

• Raw count: 31 fewer strokes vs 39 more major bleeding events (ITT vs on-treatment comparison)
• However, severity asymmetry: 45% of aspirin-arm strokes caused permanent disability or death; ~90% of apixaban-arm bleeds were fully reversible
• Authors conclude: qualitative severity difference strongly favours anticoagulation for patients with elevated stroke risk (mean CHA₂DS₂-VASc 3.9)
• Deaths were similar between groups (22.7% apixaban vs 21.9% aspirin)

Contextualising NOAH-AFNET 6 Discordance

• NOAH-AFNET 6: edoxaban vs placebo in 2,538 similar patients; primary outcome included CV death + stroke/SE → neutral result; stopped early for futility
• Three explanations for discordance:
  1. Underpowering: only 49 ischemic strokes in NOAH vs 141 in ARTESIA — far fewer events
  2. Diluted primary outcome: adding CV death (rarely attributable to stroke in this population) masks any stroke-reduction signal
  3. Comparator difference: NOAH used placebo; ARTESIA used aspirin — aspirin reduces stroke modestly but increases bleeding, equalising the bleeding signal but not the stroke signal
• ARTESIA aspirin comparator probably had minimal impact on stroke benefit but attenuated the relative bleeding harm of apixaban

Applicability and Scope

• Results directly applicable to: patients with implanted CIEDs (pacemaker, ICD, ICM) with SCAF 6 min–24 h and CHA₂DS₂-VASc ≥3
• Not directly applicable to: SCAF detected by wearable or consumer devices (Apple Watch, Fitbit, patch monitor), shorter episodes, or lower CHA₂DS₂-VASc scores
• As wearable detection proliferates, ARTESIA results may inform management decisions in consumer-detected populations — but extrapolation requires caution

Limitations of the Document

• Aspirin as comparator (rather than placebo) complicates interpretation of absolute bleeding risk with apixaban; net benefit vs placebo would differ
• Trial underpowered relative to original sample size assumptions (fewer than planned primary events due to slow enrollment and lower-than-expected event rate; medication supply ran out, necessitating early termination)
• SCAF defined only as 6 min–24 h; results do not apply to episodes <6 min (minimal risk) or >24 h (treated as clinical AF in guidelines)
• Predominantly older (mean age 76.8), white, CIED-implanted population; generalizability to younger or non-CIED populations limited
• Open-label OAC crossover (~24% per arm) may have attenuated the treatment effect — favours a larger true benefit
• Bristol-Myers Squibb–Pfizer provided funding (though no role in analysis)

Key Concepts Mentioned

• concepts/Subclinical-AF — primary subject; OAC threshold evidence
• concepts/CHA2DS2-VA — stroke risk stratification; trial enrolled CHA₂DS₂-VASc ≥3
• concepts/AF-CARE — stroke prevention pillar directly addressed

Key Entities Mentioned

• entities/Atrial-Fibrillation — upstream progression from SCAF to clinical AF (~24% over 18 months)

Wiki Pages Updated

• wiki/sources/apixaban-scaf-artesia-nejm-2024.md — created (this file)
• wiki/concepts/Subclinical-AF.md — updated with ARTESIA detailed data; corrected bleeding HR error (1.36→1.80)
• wiki/sourceindex.md — updated
• wiki/wikiindex.md — updated